

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A94A9394F225EN.html>

Date: September 2020

Pages: 122

Price: US\$ 3,500.00 (Single User License)

ID: A94A9394F225EN

Abstracts

Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020

SUMMARY

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 27 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The latest report Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020, outlays comprehensive information on the Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Aryl hydrocarbon receptor is a protein encoded by the AHR gene. It mediates biochemical and toxic effects of halogenated aromatic hydrocarbons. It involved in cell-cycle regulation. It plays an important role in the development and maturation of many tissues. It regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 2, 13 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Dermatology, Gastrointestinal, Infectious Disease, Metabolic Disorders, Ophthalmology, Genetic Disorders and Respiratory which include indications Coronavirus Disease 2019 (COVID-19), Psoriasis, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Atopic Dermatitis (Atopic Eczema), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer,

Multiple Sclerosis, Triple-Negative Breast Cancer (TNBC), Type 1 Diabetes (Juvenile Diabetes), Uveitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Respiratory Distress Syndrome, Adrenoleukodystrophy (Adrenomyeloneuropathy/Schilder-Addison Complex), Alopecia, Androgen-Sensitive Prostate Cancer, Blepharitis, Burkitt Lymphoma, Celiac Disease, Crohn's Disease (Regional Enteritis), Dengue Fever, Globoid Cell Leukodystrophy (Krabbe Disease), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hematopoietic Stem Cell Transplantation, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Mantle Cell Lymphoma, Melanoma, Metachromatic Leukodystrophy (MLD), Mucopolysaccharidosis I (MPS I) (Hurler Syndrome), Multiple Myeloma (Kahler Disease), Myasthenia Gravis, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Oral Cancer, Osteoarthritis Pain, Pancreatic Ductal Adenocarcinoma, Pemphigus, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, T-Cell Lymphomas, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Vitiligo, Wet (Neovascular/Exudative) Macular Degeneration and Zika Virus Infections.

Furthermore, this report also reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR)

The report reviews Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics and enlists all their major and minor projects

The report assesses Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Overview

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Development

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Therapeutics Assessment

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Companies Involved in Therapeutics Development

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Drug Profiles

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Dormant Products

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Discontinued Products

Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Indications, H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020

Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020

Number of Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020

Products under Development by Companies, H2 2020 (Contd..1), H2 2020

Products under Development by Companies, H2 2020 (Contd..2), H2 2020

Products under Development by Companies, H2 2020 (Contd..3), H2 2020

Number of Products under Investigation by Universities/Institutes, H2 2020

Products under Investigation by Universities/Institutes, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Stage and Route of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

Pipeline by Actavalon Inc, H2 2020

Pipeline by Active Biotech AB, H2 2020

Pipeline by Ampio Pharmaceuticals Inc, H2 2020

Pipeline by AnToIRx Inc, H2 2020

Pipeline by Bayer AG, H2 2020

Pipeline by Dermavant Sciences Inc, H2 2020

Pipeline by Hercules Pharmaceuticals BV, H2 2020

Pipeline by Hutchison MediPharma Ltd, H2 2020

Pipeline by Ikena Oncology Inc, H2 2020

Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020

Pipeline by Magenta Therapeutics Inc, H2 2020

Pipeline by Pfizer Inc, H2 2020

Pipeline by Phenex Pharmaceuticals AG, H2 2020

Pipeline by Shenogen Pharma Group Ltd, H2 2020

Pipeline by Sol-Gel Technologies Ltd, H2 2020

Pipeline by Welichem Biotech Inc, H2 2020

Dormant Products, H2 2020

Dormant Products, H2 2020 (Contd..1), H2 2020

Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Actavalon Inc
Active Biotech AB
Ampio Pharmaceuticals Inc
AnToIRx Inc
Bayer AG
Dermavant Sciences Inc
Hercules Pharmaceuticals BV
Hutchison MediPharma Ltd
Ikena Oncology Inc
JAGUAHR Therapeutics Pte Ltd
Magenta Therapeutics Inc
Pfizer Inc
Phenex Pharmaceuticals AG
Shenogen Pharma Group Ltd
Sol-Gel Technologies Ltd
Welichem Biotech Inc

I would like to order

Product name: Aryl Hydrocarbon Receptor - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A94A9394F225EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A94A9394F225EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970